Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

@article{White2021PlitidepsinHP,
  title={Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A},
  author={Kris M. White and Romel Rosales and Soner Yildiz and Thomas Kehrer and Lisa Miorin and Elena Moreno and Sonia Jangra and Melissa B. Uccellini and Raveen Rathnasinghe and Lynda Coughlan and Carles Mart{\'i}nez-Romero and Jyoti Batra and Ajda Rojc and Mehdi Bouhaddou and Jacqueline M. Fabius and Kirsten Obernier and Marion Dejosez and Mar{\'i}a Jos{\'e} Guill{\'e}n and Alejandro Losada and Pablo M. Avil{\'e}s and Michael Schotsaert and Thomas P. Zwaka and Marco Vignuzzi and Kevan M. Shokat and Nevan J. Krogan and Adolfo Garc{\'i}a-Sastre},
  journal={Science (New York, N.y.)},
  year={2021},
  volume={371},
  pages={926 - 931}
}
Hurting the virus by targeting the host Many host proteins play a role in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some are required for viral replication and translation. There are efforts toward finding drugs that target viral proteins, but a complementary approach is to target these required host proteins. White et al. explored the antiviral activity of the cyclic depsipeptide drug plitidepsin, which targets the hosts cell's translational machinery… Expand
Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19
TLDR
Current clinical evidence is inadequate for plitidepsin registration in COVID-19 patients, and multicentre trials on the drug’s efficacy, potentially also studying populations of emerging SARS-CoV-2 lineages are warranted. Expand
The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication
TLDR
It is shown that cobicistat, which is an-FDA approved drug-booster that blocks the activity of the drug metabolizing proteins Cytochrome P450-3As (CYP3As) and P-glycoprotein (P-gp), inhibits SARS-CoV-2 replication. Expand
Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals
TLDR
It was revealed that the expression of these genes is associated with COVID-19 patient severity and has predictive power on anti-SARS-CoV-2 efficacy in vitro, and drugs co-targeting cholesterol homeostasis and microtubule cytoskeleton organization processes more likely present a synergistic effect with antivirals. Expand
A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses
The SARS-CoV-2 outbreak has highlighted the need for broad-spectrum antivirals against coronaviruses (CoVs). Here, pheophorbide a (Pba) was identified as a highly active antiviral molecule againstExpand
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
TLDR
The potential therapeutic targets involved in the life cycle of the virus are summarized and small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection. Expand
Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses
TLDR
Sulforaphane is a promising treatment for prevention of coronavirus infection or treatment of early disease and interactions with remdesivir and SFN interacted synergistically to inhibit coronav virus infection in vitro. Expand
Current Strategies of Antiviral Drug Discovery for COVID-19
TLDR
The current status of the drug discovery efforts against COVID-19 and potential future directions is discussed, with the ever-increasing movability of human population and globalization of world economy, emerging and reemerging viral infectious diseases seriously threaten public health. Expand
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
  • M. Martinez
  • Medicine
  • Antimicrobial Agents and Chemotherapy
  • 2021
TLDR
Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may be a promising alternative COVID-19 therapeutic. Expand
Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS-CoV-2
TLDR
It is demonstrated that methylene blue and mycophenolic acid, two broadly available low cost compounds, strongly inhibited shedding of infectious SARS-CoV-2 at the apical side of the cultures, in either pre- or post-exposure regimens, with somewhat weaker effects on viral RNA release indicated by RT-qPCR measurements. Expand
Novel Human Lung Tissue Model for the Study of SARS-CoV-2 Entry, Inflammation and New Therapeutics
TLDR
It is shown that the HLT model preserves its main cell populations, maintains the expression of proteins required for Sars-CoV-2 infection, and identifies alveolar type II (AT-II) cells as the most susceptible cell targets for SARS-Cov-2 in the human lung. Expand
...
1
2
3
4
5
...

References

SHOWING 1-9 OF 9 REFERENCES
An inflammatory cytokine signature predicts COVID-19 severity and survival
TLDR
It is proposed that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options. Expand
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
TLDR
Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19, and some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. Expand
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
TLDR
Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilzumab, and the findings may be susceptible to unmeasured confounding. Expand
Aplidin PharmaMar.
  • L. Yao
  • Medicine
  • IDrugs : the investigational drugs journal
  • 2003
Aplidin is a cell cycle inhibitor being developed by PharmaMar SA for the potential treatment of a variety of cancers, including non-Hodgkin's lymphoma (NHL), non-small-cell lung cancer (NSCLC),Expand
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
TLDR
Maximal interleukin-6 levels before intubation showed the strongest association with the need of mechanical ventilation followed by maximal CRP, suggesting the possibility of using IL-6 or CRP levels to guide escalation of treatment in patients with COVID-19 related hyperinflammatory syndrome. Expand
Middle East respiratory syndrome coronavirus (MERS-CoV)
TLDR
Coronavirus memiliki famili besar yang menyebabkan penyakit pada manusia dan hewan dengan gejala mulai dari common cold sampai Severe Acute Respiratory Syndrome (SARS). Expand
Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
  • 2020
Morande et al., Invest
  • New Drugs 30,
  • 2012